Impact in Healthcare
The specific strain RHT3201, here known as LR, may potentially confer
benefits to pediatric patients with AD to relieve symptoms, based on low
certainty of evidence. Although the effect did not reach clinical
significance, further research on the optimal dose and duration of
treatment using LR may be explored. LR showed favorable safety outcomes
based on moderate certainty of evidence. As the age of the participants
in the trials included for this study are considerably broad,
suggestions on the optimal age for postbiotic administration in AD
treatment cannot be made.